Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Diagnostic value of insulinoma-associated protein 1 (INSM1) and comparison with established neuroendocrine markers in pulmonary cancers

Staaf, Johan LU orcid ; Tran, Lena LU ; Söderlund, Linnea ; Nodin, Björn LU ; Jirström, Karin LU orcid ; Vidarsdottir, Halla LU ; Planck, Maria LU ; Mattsson, Johanna S.M. ; Botling, Johan and Micke, Patrick , et al. (2020) In Archives of Pathology and Laboratory Medicine 144(9). p.1075-1085
Abstract

Context.-The diagnostic distinction of pulmonary neuroendocrine (NE) tumors from non-small cell lung carcinomas (NSCLCs) is clinically relevant for prognostication and treatment. Diagnosis is based on morphology and immunohistochemical staining. Objective.-To determine the diagnostic value of insulinoma-associated protein 1 (INSM1), in comparison with established NE markers, in pulmonary tumors. Design.-Fifty-four pulmonary NE tumors and 632 NSCLCs were stained for INSM1, CD56, chromogranin A, and synaptophysin. In a subset, gene expression data were available for analysis. Also, 419 metastases to the lungs were stained for INSM1. A literature search identified 39 additional studies with data on NE markers in lung cancers from the last... (More)

Context.-The diagnostic distinction of pulmonary neuroendocrine (NE) tumors from non-small cell lung carcinomas (NSCLCs) is clinically relevant for prognostication and treatment. Diagnosis is based on morphology and immunohistochemical staining. Objective.-To determine the diagnostic value of insulinoma-associated protein 1 (INSM1), in comparison with established NE markers, in pulmonary tumors. Design.-Fifty-four pulmonary NE tumors and 632 NSCLCs were stained for INSM1, CD56, chromogranin A, and synaptophysin. In a subset, gene expression data were available for analysis. Also, 419 metastases to the lungs were stained for INSM1. A literature search identified 39 additional studies with data on NE markers in lung cancers from the last 15 years. Seven of these included data on INSM1. Results.-A positive INSM1 staining was seen in 39 of 54 NE tumors (72%) and 6 of 623 NSCLCs (1%). The corresponding numbers were 47 of 54 (87%) and 14 of 626 (2%) for CD56, 30 of 54 (56%) and 6 of 629 (1%) for chromogranin A, and 46 of 54 (85%) and 49 of 630 (8%) for synaptophysin, respectively. Analysis of literature data revealed that CD56 and INSM1 were the best markers for identification of high-grade NE pulmonary tumors when considering both sensitivity and specificity, while synaptophysin also showed good sensitivity. INSM1 gene expression was clearly associated with NE histology. Conclusions.-The solid data of both our and previous studies confirm the diagnostic value of INSM1 as a NE marker in pulmonary pathology. The combination of CD56 with INSM1 and/or synaptophysin should be the first-hand choice to confirm pulmonary high-grade NE tumors. INSM1 gene expression could be used to predict NE tumor histology.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Archives of Pathology and Laboratory Medicine
volume
144
issue
9
pages
11 pages
publisher
College of American Pathologists
external identifiers
  • pmid:31913660
  • scopus:85084375328
ISSN
0003-9985
DOI
10.5858/arpa.2019-0250-OA
project
Histopathological and molecular diagnostics of lung cancer
language
English
LU publication?
yes
id
2551d6e2-0c9b-4929-a824-18fc14d3c80a
date added to LUP
2020-12-22 10:44:57
date last changed
2024-04-17 21:38:47
@article{2551d6e2-0c9b-4929-a824-18fc14d3c80a,
  abstract     = {{<p>Context.-The diagnostic distinction of pulmonary neuroendocrine (NE) tumors from non-small cell lung carcinomas (NSCLCs) is clinically relevant for prognostication and treatment. Diagnosis is based on morphology and immunohistochemical staining. Objective.-To determine the diagnostic value of insulinoma-associated protein 1 (INSM1), in comparison with established NE markers, in pulmonary tumors. Design.-Fifty-four pulmonary NE tumors and 632 NSCLCs were stained for INSM1, CD56, chromogranin A, and synaptophysin. In a subset, gene expression data were available for analysis. Also, 419 metastases to the lungs were stained for INSM1. A literature search identified 39 additional studies with data on NE markers in lung cancers from the last 15 years. Seven of these included data on INSM1. Results.-A positive INSM1 staining was seen in 39 of 54 NE tumors (72%) and 6 of 623 NSCLCs (1%). The corresponding numbers were 47 of 54 (87%) and 14 of 626 (2%) for CD56, 30 of 54 (56%) and 6 of 629 (1%) for chromogranin A, and 46 of 54 (85%) and 49 of 630 (8%) for synaptophysin, respectively. Analysis of literature data revealed that CD56 and INSM1 were the best markers for identification of high-grade NE pulmonary tumors when considering both sensitivity and specificity, while synaptophysin also showed good sensitivity. INSM1 gene expression was clearly associated with NE histology. Conclusions.-The solid data of both our and previous studies confirm the diagnostic value of INSM1 as a NE marker in pulmonary pathology. The combination of CD56 with INSM1 and/or synaptophysin should be the first-hand choice to confirm pulmonary high-grade NE tumors. INSM1 gene expression could be used to predict NE tumor histology.</p>}},
  author       = {{Staaf, Johan and Tran, Lena and Söderlund, Linnea and Nodin, Björn and Jirström, Karin and Vidarsdottir, Halla and Planck, Maria and Mattsson, Johanna S.M. and Botling, Johan and Micke, Patrick and Brunnström, Hans}},
  issn         = {{0003-9985}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{1075--1085}},
  publisher    = {{College of American Pathologists}},
  series       = {{Archives of Pathology and Laboratory Medicine}},
  title        = {{Diagnostic value of insulinoma-associated protein 1 (INSM1) and comparison with established neuroendocrine markers in pulmonary cancers}},
  url          = {{http://dx.doi.org/10.5858/arpa.2019-0250-OA}},
  doi          = {{10.5858/arpa.2019-0250-OA}},
  volume       = {{144}},
  year         = {{2020}},
}